On February 11th, The IIBR hosted the entering Mayor of Ness Ziona, Mr. Shmuel Boxer along with his deputy Mr. Ariel Almog and the director general of the municipality Mrs. Dafna Kiro-Cohen.
Prof. Shmuel C. Shapira, Director General of the institute, gave an overall look at the institute's scientific achievements, emphasizing excellence as a core value in its work, as well as its community engagements program "Encounters with the institute scientists" a volunteering program consist of inspirational session designed to nurture scientific education.
The Mayor expressed his appreciation for the institute scientific work and its contribution to the community.
At the ceremony held at the Council for a Beautiful Israel house(December 26, 2018), the Israeli Institute for Biological Research awarded a certificate of 5 beauty stars for quality of life and a sustainable environment.
The National Biological Laboratory of the Israel Institute for Biological Research
identified the Monkeypox virus in a patient who returned from a visit to
In the picture: An image of the virus as obtained by the transmission
electron microscope at the Institute.
Wind turbines, urban planning and air pollution prevention: The new facility by the Israel Institute for Biological Research serves as a platform for conducting a variety of environmental experiments, without ever leaving the laboratory
Worldwide exclusive: A first-ever visit to the Israel Institute for Biological Research and an interview with its director, Col. (res.) Prof. Shmuel Shapira, who sheds some light on the secrets and operations of the mysterious institute.
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a research and development collaboration with the Israel Institute for Biological Research (“IIBR”) to further advance its C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, to combat emerging diseases and threats.
We welcome you to contact us for any question or offer for collaborations.
Enter your full name please.
Choose your country phone code.
Enter your phone number.
Enter your e-mail address.
Select the derpartment you wish to contact with.
If you have any message to deliver, please write it here.
There are some errors in your form.
the mail is recived, thank you